Literature DB >> 25359866

Use and misuse of waterfall plots.

Tiffany Shao1, Lisa Wang1, Arnoud J Templeton1, Raymond Jang1, Francisco W Vera-Badillo1, Mairead G McNamara1, Myles Margolis1, Tae Kyoung Kim1, Mehrdad Sinaei1, Hassan Shoushtari1, Ian F Tannock2.   

Abstract

BACKGROUND: "Waterfall plots" are used to describe changes in tumor size observed in clinical studies. Here we assess criteria for generation of waterfall plots and the impact of measurement error in generating them.
METHODS: We reviewed published waterfall plots to investigate variability in criteria used to define them. We then compared waterfall plots generated by different observers for 24 patients enrolled in a completed phase I study of solid tumors with available computed tomography (CT) scans. Tumor measurements were made independently from CT scans according to Response Evaluation Criteria in Solid Tumors 1.1 by four board-certified radiologists and four medical oncologists. Interobserver variability was quantified and compared with reference measurements reported for the phase 1 study. All statistical tests were two-sided.
RESULTS: There was substantial variability in criteria used to generate published waterfall plots. In the internal study, the results were statistically significantly different between all eight readers (P = .01, variance = 197.1, SD = 14.0) and between the oncologists (P = .01, variance = 319.0, SD = 17.9), but not between the radiologists (P = .68, variance = 70.8, SD = 8.4). Different observers classified one to five patients as having a partial response and 12-19 patients as having stable disease. Similar variability in categorization of response was observed when these error rates were applied to published waterfall plots.
CONCLUSION: Waterfall plots are subject to substantial variability in criteria used to define them and are influenced by measurement errors; they should be generated by trained radiologists. Caution should be exercised when interpreting results of waterfall plots in the context of clinical trials.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25359866     DOI: 10.1093/jnci/dju331

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  11 in total

Review 1.  Current and Evolving Methods to Visualize Biological Data in Cancer Research.

Authors:  Puey Ling Chia; Craig Gedye; Paul C Boutros; Paul Wheatley-Price; Thomas John
Journal:  J Natl Cancer Inst       Date:  2016-05-31       Impact factor: 13.506

2.  ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases.

Authors:  Nikhil Goyal; Andrea B Apolo; Eliana D Berman; Mohammad Hadi Bagheri; Jason E Levine; John W Glod; Rosandra N Kaplan; Laura B Machado; Les R Folio
Journal:  J Digit Imaging       Date:  2017-06       Impact factor: 4.056

3.  Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

Authors:  Chul Kim; Vinay Prasad
Journal:  Mayo Clin Proc       Date:  2016-05-10       Impact factor: 7.616

4.  Motor deficits at presentation and predictors of overall survival in central nervous system lymphomas.

Authors:  Yu Tung Lo; Ya Lyn Samantha Ang; Valerie Shiwen Yang; Dave Thevandiran Kanavathy; Sai Liang; Lester Lee
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

5.  Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.

Authors:  Hui Li; Miaofang Wu; Zhuna Wu; Jinxiao Liang; Lijuan Wang; Xi Yang; Zhongqiu Lin; Jing Li
Journal:  Cancer Immunol Immunother       Date:  2021-11-01       Impact factor: 6.968

6.  Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma.

Authors:  Angelo Della Corte; Claudio Sallemi; Francesca Ratti; Lorenzo Monfardini; Simone Gusmini; Federica Cipriani; Renato Pennella; Domenico Santangelo; Valentina Burgio; Andrea Casadei-Gardini; Luca Aldrighetti; Francesco De Cobelli
Journal:  Cardiovasc Intervent Radiol       Date:  2022-09-30       Impact factor: 2.797

7.  Accounting for All Patients in Waterfall Plots.

Authors:  James Moon; Michael LeBlanc; Megan Othus
Journal:  JCO Clin Cancer Inform       Date:  2021-04

8.  Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.

Authors:  Myung Sun Kim; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03

9.  Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.

Authors:  Takashi Kobayashi; Katsuhiro Ito; Takahiro Kojima; Satoru Maruyama; Shoichiro Mukai; Masakazu Tsutsumi; Jun Miki; Tomoya Okuno; Yuko Yoshio; Hiroaki Matsumoto; Toru Shimazui; Takehiko Segawa; Takashi Karashima; Kimihiko Masui; Fumimasa Fukuta; Kojiro Tashiro; Kazuto Imai; Shigetaka Suekane; Seiji Nagasawa; Shin Higashi; Tomohiro Fukui; Osamu Ogawa; Hiroshi Kitamura; Hiroyuki Nishiyama
Journal:  Cancer Immunol Immunother       Date:  2021-07-07       Impact factor: 6.968

Review 10.  Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.

Authors:  Giuseppe Aprile; Caterina Fontanella; Marta Bonotto; Karim Rihawi; Stefania Eufemia Lutrino; Laura Ferrari; Mariaelena Casagrande; Elena Ongaro; Massimiliano Berretta; Antonio Avallone; Gerardo Rosati; Francesco Giuliani; Gianpiero Fasola
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.